PTHS Key Statistics, Chart & Performance
The current stock price of PTHS is 26.57 USD. In the past month the price decreased by -29%.
PTHS Latest News, Press Relases and Analysis
PTHS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About PTHS
Company Profile
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Company Info
PELTHOS THERAPEUTICS INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA US
Employees: 4
Phone: 19199082422
PELTHOS THERAPEUTICS INC / PTHS FAQ
What does PELTHOS THERAPEUTICS INC do?
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Can you provide the latest stock price for PELTHOS THERAPEUTICS INC?
The current stock price of PTHS is 26.57 USD. The price increased by 0.8% in the last trading session.
Does PELTHOS THERAPEUTICS INC pay dividends?
PTHS does not pay a dividend.
How is the ChartMill rating for PELTHOS THERAPEUTICS INC?
PTHS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the PE ratio for PTHS stock?
PELTHOS THERAPEUTICS INC (PTHS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.08).
PTHS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PTHS.
PTHS Financial Highlights
Over the last trailing twelve months PTHS reported a non-GAAP Earnings per Share(EPS) of -12.08. The EPS decreased by -2876.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1098.3% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTHS Forecast & Estimates
8 analysts have analysed PTHS and the average price target is 67.32 USD. This implies a price increase of 153.37% is expected in the next year compared to the current price of 26.57.